Does the media favor VRDN or PACS?

In the previous week, PACS Group had 13 more articles in the media than Viridian Therapeutics. MarketBeat recorded 16 mentions for PACS Group and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat PACS Group's score of 0.07 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PACS Group 4 Very Positive mention(s) 7 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to VRDN or BLLN?

In the previous week, Billiontoone had 14 more articles in the media than Viridian Therapeutics. MarketBeat recorded 17 mentions for Billiontoone and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat Billiontoone's score of -0.17 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Billiontoone 8 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to RDNT or VRDN?

In the previous week, RadNet and RadNet both had 3 articles in the media. RadNet's average media sentiment score of 1.38 beat Viridian Therapeutics' score of 1.22 indicating that RadNet is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RadNet 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer VRDN or CELC?

In the previous week, Celcuity had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 4 mentions for Celcuity and 3 mentions for Viridian Therapeutics. Celcuity's average media sentiment score of 1.76 beat Viridian Therapeutics' score of 1.22 indicating that Celcuity is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor CAI or VRDN?

In the previous week, Caris Life Sciences had 6 more articles in the media than Viridian Therapeutics. MarketBeat recorded 9 mentions for Caris Life Sciences and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat Caris Life Sciences' score of 1.04 indicating that Viridian Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Caris Life Sciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Viridian Therapeutics (VRDN) Competitors

$18.99 -0.75 (-3.80%)

Closing price 07/13/2026 04:00 PM Eastern

Extended Trading

$19.07 +0.08 (+0.42%)

As of 07:45 AM Eastern

Compare

VRDN vs. PACS, BLLN, RDNT, CELC, and CAI

Should you buy Viridian Therapeutics stock or one of its competitors? MarketBeat compares Viridian Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Viridian Therapeutics include PACS Group (PACS), Billiontoone (BLLN), RadNet (RDNT), Celcuity (CELC), and Caris Life Sciences (CAI). These companies are all part of the "healthcare" industry.

How does Viridian Therapeutics compare to PACS Group?

Viridian Therapeutics (NASDAQ:VRDN) and PACS Group (NYSE:PACS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Viridian Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market. Comparatively, PACS Group has a beta of -0.08, indicating that its share price is 108% less volatile than the broader market.

PACS Group has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than PACS Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	27.63	-$342.60M	-$3.32	N/A
PACS Group	$5.29B	1.30	$191.54M	$1.56	27.75

PACS Group has a net margin of 4.49% compared to Viridian Therapeutics' net margin of -490.31%. PACS Group's return on equity of 26.47% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
PACS Group	4.49%	26.47%	4.36%

Viridian Therapeutics presently has a consensus price target of $38.79, suggesting a potential upside of 104.24%. PACS Group has a consensus price target of $50.60, suggesting a potential upside of 16.88%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than PACS Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
PACS Group	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, PACS Group had 13 more articles in the media than Viridian Therapeutics. MarketBeat recorded 16 mentions for PACS Group and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat PACS Group's score of 0.07 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PACS Group	4 Very Positive mention(s)	7 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

PACS Group beats Viridian Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Viridian Therapeutics compare to Billiontoone?

Viridian Therapeutics (NASDAQ:VRDN) and Billiontoone (NASDAQ:BLLN) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, media sentiment and institutional ownership.

Viridian Therapeutics presently has a consensus target price of $38.79, indicating a potential upside of 104.24%. Billiontoone has a consensus target price of $126.00, indicating a potential upside of 2.23%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Viridian Therapeutics is more favorable than Billiontoone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Billiontoone has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -490.31%. Billiontoone's return on equity of 0.00% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Billiontoone	N/A	N/A	N/A

In the previous week, Billiontoone had 14 more articles in the media than Viridian Therapeutics. MarketBeat recorded 17 mentions for Billiontoone and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat Billiontoone's score of -0.17 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Billiontoone	8 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Billiontoone has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	27.63	-$342.60M	-$3.32	N/A
Billiontoone	$305.11M	18.58	$7.45M	$0.55	224.09

Summary

Billiontoone beats Viridian Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Viridian Therapeutics compare to RadNet?

RadNet (NASDAQ:RDNT) and Viridian Therapeutics (NASDAQ:VRDN) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, earnings, media sentiment, institutional ownership and risk.

In the previous week, RadNet and RadNet both had 3 articles in the media. RadNet's average media sentiment score of 1.38 beat Viridian Therapeutics' score of 1.22 indicating that RadNet is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
RadNet	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

RadNet has higher revenue and earnings than Viridian Therapeutics. RadNet is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RadNet	$2.04B	2.44	-$18.65M	-$0.18	N/A
Viridian Therapeutics	$70.85M	27.63	-$342.60M	-$3.32	N/A

RadNet presently has a consensus price target of $87.43, indicating a potential upside of 38.10%. Viridian Therapeutics has a consensus price target of $38.79, indicating a potential upside of 104.24%. Given Viridian Therapeutics' higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than RadNet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RadNet	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

77.9% of RadNet shares are owned by institutional investors. 5.6% of RadNet shares are owned by company insiders. Comparatively, 2.4% of Viridian Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

RadNet has a net margin of -0.66% compared to Viridian Therapeutics' net margin of -490.31%. RadNet's return on equity of 2.77% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
RadNet	-0.66%	2.77%	0.97%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

RadNet has a beta of 1.37, suggesting that its share price is 37% more volatile than the broader market. Comparatively, Viridian Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Summary

RadNet beats Viridian Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Viridian Therapeutics compare to Celcuity?

Viridian Therapeutics (NASDAQ:VRDN) and Celcuity (NASDAQ:CELC) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Celcuity has a net margin of 0.00% compared to Viridian Therapeutics' net margin of -490.31%. Viridian Therapeutics' return on equity of -80.19% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-490.31%	-80.19%	-48.84%
Celcuity	N/A	-244.61%	-50.22%

63.3% of Celcuity shares are owned by institutional investors. 2.4% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Viridian Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.16, suggesting that its share price is 84% less volatile than the broader market.

Viridian Therapeutics currently has a consensus price target of $38.79, suggesting a potential upside of 104.24%. Celcuity has a consensus price target of $152.09, suggesting a potential upside of 46.54%. Given Viridian Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Viridian Therapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Celcuity has lower revenue, but higher earnings than Viridian Therapeutics. Celcuity is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$70.85M	27.63	-$342.60M	-$3.32	N/A
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

In the previous week, Celcuity had 1 more articles in the media than Viridian Therapeutics. MarketBeat recorded 4 mentions for Celcuity and 3 mentions for Viridian Therapeutics. Celcuity's average media sentiment score of 1.76 beat Viridian Therapeutics' score of 1.22 indicating that Celcuity is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Viridian Therapeutics beats Celcuity on 9 of the 15 factors compared between the two stocks.

How does Viridian Therapeutics compare to Caris Life Sciences?

Caris Life Sciences (NASDAQ:CAI) and Viridian Therapeutics (NASDAQ:VRDN) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Caris Life Sciences has a net margin of 3.75% compared to Viridian Therapeutics' net margin of -490.31%. Caris Life Sciences' return on equity of 98.28% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Caris Life Sciences	3.75%	98.28%	48.87%
Viridian Therapeutics	-490.31%	-80.19%	-48.84%

Caris Life Sciences presently has a consensus target price of $26.11, suggesting a potential upside of 53.05%. Viridian Therapeutics has a consensus target price of $38.79, suggesting a potential upside of 104.24%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Viridian Therapeutics is more favorable than Caris Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86

In the previous week, Caris Life Sciences had 6 more articles in the media than Viridian Therapeutics. MarketBeat recorded 9 mentions for Caris Life Sciences and 3 mentions for Viridian Therapeutics. Viridian Therapeutics' average media sentiment score of 1.22 beat Caris Life Sciences' score of 1.04 indicating that Viridian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Caris Life Sciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caris Life Sciences	$812.03M	5.94	-$68.09M	-$7.61	N/A
Viridian Therapeutics	$70.85M	27.63	-$342.60M	-$3.32	N/A

Summary

Caris Life Sciences beats Viridian Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Viridian Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRDN vs. The Competition

Export

Metric	Viridian Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.03B	$3.71B	$7.05B	$12.61B
Dividend Yield	N/A	2.20%	2.68%	8.00%
P/E Ratio	-5.72	20.85	27.12	24.26
Price / Sales	27.63	314.01	587.25	117.88
Price / Cash	N/A	61.98	29.22	49.36
Price / Book	3.07	8.49	10.89	6.29
Net Income	-$342.60M	$23.83M	$3.58B	$330.66M
7 Day Performance	-7.23%	-3.56%	-2.11%	-1.35%
1 Month Performance	16.15%	6.31%	3.28%	-0.64%
1 Year Performance	10.79%	48.30%	26.33%	19.08%

Viridian Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRDN Viridian Therapeutics	3.7371 of 5 stars	$18.99 -3.8%	$38.79 +104.2%	+11.4%	$2.03B	$70.85M	N/A	50	Positive News Analyst Downgrade
PACS PACS Group	3.3652 of 5 stars	$44.68 +0.5%	$48.00 +7.4%	+242.5%	$7.04B	$5.29B	28.51	47,455
BLLN Billiontoone	1.7456 of 5 stars	$123.40 +2.5%	$126.00 +2.1%	N/A	$5.54B	$305.11M	N/A	620	News Coverage Insider Trade
RDNT RadNet	3.6161 of 5 stars	$68.92 +0.2%	$87.43 +26.9%	+14.1%	$5.41B	$2.04B	N/A	11,264	Positive News
CELC Celcuity	3.7078 of 5 stars	$108.58 +0.6%	$152.09 +40.1%	+661.5%	$5.26B	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRDN) was last updated on 7/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Viridian Therapeutics (VRDN) Competitors

VRDN vs. PACS, BLLN, RDNT, CELC, and CAI

How does Viridian Therapeutics compare to PACS Group?

Summary

How does Viridian Therapeutics compare to Billiontoone?

Summary

How does Viridian Therapeutics compare to RadNet?

Summary

How does Viridian Therapeutics compare to Celcuity?

Summary

How does Viridian Therapeutics compare to Caris Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Viridian Therapeutics (VRDN) Competitors

VRDN vs. PACS, BLLN, RDNT, CELC, and CAI

How does Viridian Therapeutics compare to PACS Group?

Which has more risk & volatility, VRDN or PACS?

Which has better valuation & earnings, VRDN or PACS?

Is VRDN or PACS more profitable?

Do analysts recommend VRDN or PACS?

Does the media favor VRDN or PACS?

Summary

How does Viridian Therapeutics compare to Billiontoone?

Do analysts recommend VRDN or BLLN?

Is VRDN or BLLN more profitable?

Does the media refer more to VRDN or BLLN?

Which has higher valuation & earnings, VRDN or BLLN?

Summary

How does Viridian Therapeutics compare to RadNet?

Does the media refer more to RDNT or VRDN?

Which has preferable valuation and earnings, RDNT or VRDN?

Do analysts rate RDNT or VRDN?

Do institutionals & insiders believe in RDNT or VRDN?

Is RDNT or VRDN more profitable?

Which has more volatility & risk, RDNT or VRDN?

Summary

How does Viridian Therapeutics compare to Celcuity?

Is VRDN or CELC more profitable?

Do institutionals and insiders hold more shares of VRDN or CELC?

Which has more risk & volatility, VRDN or CELC?

Do analysts prefer VRDN or CELC?

Which has better valuation & earnings, VRDN or CELC?

Does the media prefer VRDN or CELC?

Summary

How does Viridian Therapeutics compare to Caris Life Sciences?

Is CAI or VRDN more profitable?

Do analysts prefer CAI or VRDN?

Does the media favor CAI or VRDN?

Which has higher valuation and earnings, CAI or VRDN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRDN vs. The Competition

Viridian Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools